Fibrodysplasia ossificans progressiva

Best Practice and Research: Clinical Rheumatology

Volumn 22, Issue 1, 2008, Pages 191-205

  Kaplan, Frederick S ^a   Le Merrer, Martine ^b   Glaser, David L ^a   Pignolo, Robert J ^c   Goldsby, Robert E ^d   Kitterman, Joseph A ^d   Groppe, Jay ^e   Shore, Eileen M ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

ACVR1; ALK2; BMP; bone morphogenetic protein; fibrodysplasia ossificans progressiva (FOP); heterotopic ossification

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DNA; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROCOLLAGEN C PROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

BONE MARROW TRANSPLANTATION; BONE PAIN; BONE SCINTISCANNING; BRACE; CARDIOPULMONARY FUNCTION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ERROR; DISEASE EXACERBATION; DNA DETERMINATION; DNA SEQUENCE; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENERAL ANESTHESIA; GENETIC PREDISPOSITION; HEARING IMPAIRMENT; HEREDITY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LINKAGE ANALYSIS; MISSENSE MUTATION; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; OSSIFICATION; OSSIFYING MYOSITIS; PHENOTYPE; PRIORITY JOURNAL; REHABILITATION CARE; REVIEW; SKELETON MALFORMATION; SPINE MALFORMATION; TEMPOROMANDIBULAR JOINT; TREATMENT CONTRAINDICATION; TREATMENT FAILURE;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; MUTATION; MYOSITIS OSSIFICANS; OSSIFICATION, HETEROTOPIC; SMAD PROTEINS;

EID: 40149099148     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2007.11.007     Document Type: Review

References (58)

1. Connor J.M., and Evans D.A. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. The Journal of Bone and Joint Surgery. British Volume 64 (1982) 76-83
2. Smith R. Fibrodysplasia (myositis) ossificans progressiva: clinical lessons from a rare disease. Clinical Orthopaedics and Related Research 346 (1988) 7-14
3. Kaplan F.S., Shore E.M., and Connor J.M. Fibrodysplasia ossificans progressiva (FOP). In: Royce P.M., and Steinmann B. (Eds). Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects. 2nd edn. (2002), Wiley-Liss, John Wiley & Sons, Inc., New York 827-840
4. Kaplan F.S., Glaser D.L., Hebela N., and Shore E.M. Heterotopic ossification. The Journal of the American Academy of Orthopaedic Surgeons 12 (2004) 116-125
5. Kaplan F.S., Glaser D.L., Shore E.M., et al. The phenotype of fibrodysplasia ossificans progressiva. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 183-188
6. Kaplan F.S., Glaser D.L., and Shore E.M. Fibrodysplasia (myositis) ossificans progressiva. In: Favus M.J. (Ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th edn. (2006), The American Society for Bone and Mineral Research, Washington, DC 450-453
7. Kaplan F.S. Fibrodysplasia ossificans progressiva: an historical perspective. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 179-181
8. Rosenstirn J.A. A contribution to the study of myositis ossificans progressiva. Annals of Surgery 68 (1918) 485-520 591-637
9. Shore E.M., Xu M., Feldman G.J., et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics 38 (2006) 525-527
10. Cohen R.B., Hahn G.V., Tabas J., et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. The Journal of Bone and Joint Surgery. American Volume 75 (1993) 215-219
11. Rocke D.M., Zasloff M., Peeper J., et al. Age and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clinical Orthopaedics and Related Research 301 (1994) 243-248
12. Kaplan F.S., Tabas J., Gannon F.H., et al. The histopathology of fibrodysplasia ossificans progressiva: an endochondral process. The Journal of Bone and Joint Surgery. American Volume 75 (1993) 220-230
13. Gannon F.H., Valentine B.A., Shore E.M., et al. Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clinical Orthopaedics and Related Research 346 (1998) 19-25
14. Glaser D.L., Economides A.N., Wang L., et al. In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. The Journal of Bone and Joint Surgery. American Volume 85 (2003) 2332-2342
15. Pignolo R.J., Suda R.K., and Kaplan F.S. The fibrodysplasia ossificans progressiva lesion. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 195-200
16. Lanchoney T.F., Cohen R.B., Rocke D.M., et al. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. The Journal of Pediatrics 126 (1995) 762-764
17. Janoff H.B., Zasloff M.A., and Kaplan F.S. Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngology-Head and Neck Surgery 114 (1996) 599-604
18. Luchetti W., Cohen R.B., Hahn G.V., et al. Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 81 (1996) 21-25
19. Glaser D.L., Rocke D.M., and Kaplan F.S. Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clinical Orthopaedics and Related Research 346 (1998) 110-116
20. Scarlett R.F., Rocke D.M., Kantanie S., et al. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva (FOP). Clinical Orthopaedics and Related Research 423 (2004) 275-279
21. Moriatis J.M., Gannon F.H., Shore E.M., et al. Limb swelling in patients who have fibrodysplasia ossificans progressiva. Clinical Orthopaedics and Related Research 336 (1997) 247-253
22. Kaplan F.S., and Glaser D.L. Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 213-216
23. Shore E.M., Feldman G.J., Xu M., and Kaplan F.S. The genetics of fibrodysplasia ossificans progressiva. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 201-204
24. Kitterman J.A., Kantanie S., Rocke D.M., and Kaplan F.S. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 116 (2005) 654-661
25. Schaffer A.A., Kaplan F.S., Tracy M.R., et al. Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome. Spine 30 (2005) 1379-1385
26. Levy C.E., Lash A.T., Janoff H.B., and Kaplan F.S. Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. American Journal of Audiology 8 (1999) 29-33
27. Shah P.B., Zasloff M.A., Drummond D., and Kaplan F.S. Spinal deformity in patients who have fibrodysplasia ossificans progressiva. The Journal of Bone and Joint Surgery. American Volume 76 (1994) 1442-1450
28. Kussmaul W.G., Esmail A.N., Sagar Y., et al. Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clinical Orthopaedics and Related Research 346 (1998) 104-109
29. Kaplan F.S., Strear C.M., and Zasloff M.A. Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clinical Orthopaedics and Related Research 304 (1994) 238-247
30. Mahboubi S., Glaser D.L., Shore E.M., and Kaplan F.S. Fibrodysplasia ossificans progressiva. Pediatric Radiology 31 (2001) 307-314
31. Einhorn T.A., and Kaplan F.S. Traumatic fractures of heterotopic bone in patients who have fibrodysplasia ossificans progressiva. Clinical Orthopaedics and Related Research 308 (1994) 173-177
32. Kaplan F.S., Sawyer J., Connors S., et al. Urinary basic fibroblast growth factor: a biochemical marker for preosseous fibroproliferative lesions in patients with FOP. Clinical Orthopaedics and Related Research 346 (1998) 59-65
33. Gannon F.H., Glaser D., Caron R., et al. Mast cell involvement in fibrodysplasia ossificans progressiva. Human Pathology 32 (2001) 842-848
34. Kaplan F.S., Glaser D.L., Shore E.M., et al. Hematopoietic stem-cell contribution to ectopic skeletogenesis. The Journal of Bone and Joint Surgery. American Volume 89 (2007) 347-357
35. Kaplan F.S., McCluskey W., Hahn G., et al. Genetic transmission of fibrodysplasia ossificans progressiva. The Journal of Bone and Joint Surgery. American Volume 75 (1993) 1214-1220
36. Hebela N., Shore E.M., and Kaplan F.S. Three pairs of monozygotic twins with fibrodysplasia ossificans progressiva: the role of environment in the progression of heterotopic ossification. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 205-208
37. Kaplan F.S., Tabas J.A., and Zasloff M.A. Fibrodysplasia ossificans progressiva: a clue from the fly?. Calcified Tissue International 47 (1990) 117-125
38. Shafritz A.B., Shore E.M., Gannon F.H., et al. Over-expression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. The New England Journal of Medicine 335 (1996) 555-561
39. Gannon F.H., Kaplan F.S., Olmsted E., et al. Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Human Pathology 28 (1997) 339-343
40. Olmsted E.A., Kaplan F.S., and Shore E.M. Bone morphogenetic protein 4 regulation in fibrodysplasia ossificans progressiva. Clinical Orthopaedics and Related Research 408 (2003) 331-343
41. Ahn J., Serrano de la Peña L., Shore E.M., and Kaplan F.S. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. The Journal of Bone and Joint Surgery. American Volume 85 (2003) 667-674
42. Hegyi L., Gannon F.H., Glaser D.L., et al. Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification. The Journal of Pathology 201 (2003) 141-148
43. Serrano de la Peña L., Billings P.C., Fiori J.L., et al. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. Journal of Bone and Mineral Research 20 (2005) 1168-1176
44. Kaplan F.S., Fiori J.L., Ahn J., et al. Dysregulation of BMP4 receptor trafficking and signaling in fibrodysplasia ossificans progressiva. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 217-223
45. Fiori J.L., Billings P.C., Serrano de la Peña L., et al. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). Journal of Bone and Mineral Research 21 (2006) 902-909
46. Kaplan F.S., Fiori J., Serrano de la Peña L., et al. Dysregulation of the BMP4 signaling pathway in fibrodysplasia ossificans progressiva. Annals of the New York Academy of Sciences 1068 (2006) 54-65
47. O'Connell M.P., Billings P.C., Fiori J.L., et al. HSPG modulation of BMP signaling in fibrodysplasia ossificans progressiva cells. Journal of Cellular Biochemistry 102 (2007) 1493-1503
48. Wang T., Li B.-Y., Danielson P.D., et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF-β family type I receptors. Cell 86 (1996) 435-444
49. Chen Y.-G., Liu F., and Massagué J. Mechanism of TGF-β receptor inhibition by FKBP12. The EMBO Journal 16 (1997) 3866-3876
50. Yamaguchi T., Kurisaki A., Yamakawa N., et al. FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor. Journal of Molecular Endocrinology 36 (2006) 569-579
51. Kaplan F.S., Glaser D.L., Pignolo R.J., and Shore E.M. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opinion on Biological Therapy 7 (2007) 705-712
52. Kaplan F.S., Shore E.M., Pignolo R.J., and Glaser D.L. Animal models of fibrodysplasia ossificans progressiva. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 229-234
53. Glaser D.L., and Kaplan F.S. Treatment considerations for the management of fibrodysplasia ossificans progressiva. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 243-250
54. Nussbaum B.L., Grunwald Z., and Kaplan F.S. Oral and dental healthcare and anesthesia for persons with fibrodysplasia ossificans progressiva. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 239-242
55. Levy C.E., Berner T.F., and Bendixen R. Rehabilitation for individuals with fibrodysplasia ossificans progressiva. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 251-256
56. Kaplan F.S., Shore E.M., Gupta R., et al. Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway. Clinical Reviews in Bone and Mineral Metabolism 3 (2005) 189-193
57. Mohler III E.R., Gannon F., Reynolds C., et al. Bone formation and inflammation in cardiac valves. Circulation 20 (2001) 1522-1528
58. Kaplan F.S. The key to the closet is the key to the kingdom: a common lesson of rare diseases. Orphan Disease Update 24 (2006) 1-9